Ixazomib improves PFS after ASCT in MM

Print Friendly, PDF & Email


Sign announcing ASH 2018
©ASH/Rodney White 2018
Ixazomib improved progression-free survival (PFS) following autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (MM) in the TOURMALINE-MM3 trial. The oral proteasome inhibitor improved PFS by 39% compared to placebo. In addition, treatment with ixazomib was well tolerated, and there was a low... [Read Article]
Print Friendly, PDF & Email

Older people with CHIP are safe donor source for HSCT

Print Friendly, PDF & Email


Bone marrow aspirate
Photo by Chad McNeeley
New research suggests older individuals with clonal hematopoiesis of indeterminate potential (CHIP) are a safe donor source for allogeneic hematopoietic stem cell transplant (HSCT). Researchers found that transplants from older donors with CHIP resulted in similar survival as transplants from older donors without CHIP. HSCT recipients with... [Read Article]
Print Friendly, PDF & Email

Study supports PBM program for HSCT recipients

Print Friendly, PDF & Email


Nilesh Jambhekar, MD
Photo by Neil Osterweil
A blood management program for patients undergoing hematopoietic stem cell transplant (HSCT) can reduce inappropriate transfusions and costs without compromising patient outcomes, a new study suggests. Researchers retrospectively compared outcomes before and after implementation of a patient blood management (PBM) program at a single institution. After the... [Read Article]
Print Friendly, PDF & Email

Changes related to AML relapse may be reversible

Print Friendly, PDF & Email


AML cells
New research suggests relapse of acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplant (HSCT) is related to changes in immune-related gene expression that may be reversible. Researchers observed downregulation of major histocompatibility complex (MHC) class II genes in samples from patients who relapsed after HSCT. However, interferon-gamma “rapidly reversed this... [Read Article]
Print Friendly, PDF & Email

Ruxolitinib under priority review for acute GVHD

Print Friendly, PDF & Email


Bottles of ruxolitinib
Photo from Business Wire
The U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental new drug application (sNDA) for the JAK1/JAK2 inhibitor ruxolitinib (Jakafi®). With this sNDA, Incyte Corporation is seeking approval for ruxolitinib as a treatment for patients with acute graft-versus-host-disease (GVHD) who have had an... [Read Article]
Print Friendly, PDF & Email

OMS721 receives orphan designation for HSCT-TMA

Print Friendly, PDF & Email


HSCT preparation
Photo by Chad McNeeley
The U.S. Food and Drug Administration (FDA) has granted OMS721 orphan designation for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). OMS721 is a monoclonal antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system. The FDA previously granted OMS721 breakthrough therapy... [Read Article]
Print Friendly, PDF & Email

Engineered MSCs could treat GVHD

Print Friendly, PDF & Email


Mesenchymal stem cells in
a hyaluronic acid hydrogel
Image by Megan Farrell
A mesenchymal stem cell (MSC) product could treat acute graft-versus-host disease (GVHD), according to preclinical research. The product, apceth-201, improved symptoms of GVHD and prolonged survival in two mouse models. Researchers described results with apceth-201 in a poster presentation at the Annual... [Read Article]
Print Friendly, PDF & Email

Inhibitor could improve HSC donation and transplant

Print Friendly, PDF & Email


HSCs in the bone marrow
Preclinical research suggests a small-molecule inhibitor could potentially improve the donation and transplant of hematopoietic stem cells (HSCs). One study showed that the inhibitor, CASIN, could improve HSC yields from murine transplant donors. Another study showed that CASIN could be used as conditioning, with or without fludarabine, in murine... [Read Article]
Print Friendly, PDF & Email

Auto-FMT restores gut microbiota after HSCT

Print Friendly, PDF & Email


Gut bacteria
A randomized, controlled study of 25 patients has demonstrated that an autologous fecal microbiota transplant (auto-FMT) can restore beneficial gut bacteria depleted during allogeneic hematopoietic stem cell transplant (auto-HSCT), according to researchers. They reported that auto-FMT is a safe and effective way to help replenish the beneficial bacteria to near baseline levels within... [Read Article]
Print Friendly, PDF & Email

FDA grants rezafungin QIDP and fast track designations

Print Friendly, PDF & Email


Photomicrograph of C albicans.
Photo from CDC.gov
The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDO) and fast track designations for rezafungin, an injection for the prevention of invasive fungal infections in adults undergoing allogeneic bone marrow transplantation. Rezafungin is a novel antifungal echinocandin being developed by Cidara Therapeutics... [Read Article]
Print Friendly, PDF & Email